Skip to content

Study · Case report or series · n = 1 · 2023

2 results

Meeting the Body Mass Index Requirement for Gender-affirming Surgery Using Antiobesity Medication.

Taormina JM, Gilden AH, Iwamoto SJ, Iwamoto SJ

JCEM case reports1 May 2023Cited by 8 (Europe PMC)

PMID37388627 (opens in a new tab)PMCIDPMC10301860 (opens in a new tab)DOI10.1210/jcemcr/luad067 (opens in a new tab)PepBankPUB-37388627
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 40-year-old transgender woman with obesity, semaglutide with monthly dose escalation, plus lifestyle counselling, led to 13.9% weight loss within 3 months.

    In plain wordsIn one transgender woman with obesity, semaglutide plus lifestyle counselling led to 13.9% weight loss in 3 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss within 3 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Measurements

    Weight loss
    13.9%
    within 3 months

    Source sentences

    Summary
    In addition to lifestyle modification counseling, she was started on semaglutide with monthly dose escalation, leading to 13.9% weight loss with a BMI of 34.1 kg/m2 within 3 months.
    1 context sentence
    Summary · context
    We report the case of a 40-year-old transgender woman with a BMI of 39.6 kg/m2 who presented for weight loss to qualify for gender-affirming bilateral breast augmentation, requiring BMI 2.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 40-year-old transgender woman with a BMI of 39.6 kg/m2, semaglutide plus lifestyle counselling lowered BMI to 34.1 kg/m2 within 3 months.

    In plain wordsIn one transgender woman with obesity, semaglutide plus lifestyle counselling lowered her BMI below the surgical limit in 3 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI after 3 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Measurements

    BMI
    34.1 kg/m2
    after 3 months

    Source sentences

    Summary
    In addition to lifestyle modification counseling, she was started on semaglutide with monthly dose escalation, leading to 13.9% weight loss with a BMI of 34.1 kg/m2 within 3 months.
    1 context sentence
    Summary · context
    We report the case of a 40-year-old transgender woman with a BMI of 39.6 kg/m2 who presented for weight loss to qualify for gender-affirming bilateral breast augmentation, requiring BMI 2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.